Julphar Reinforces Commitment to Quality Following Product Recall
- ‘We follow stringent standards to ensure safety and quality’ says GM
- Low-dose aspirin tablet recalled due to stability issues
January 24, 2019, Ras Al Khaimah (UAE) - Julphar, one of the largest pharmaceutical manufacturers in the Middle East and Africa, has issued a statement reinforcing its commitment to quality following the recall of one of its products by the UAE Ministry of Health and Prevention (MoHAP).
Jerome Carle, General Manager of Julphar, said: We can confirm that low-dose aspirin medicine, Jusprin 81mg, has been recalled by MoHAP due to an issue over its stability.
“The global nature of our business requires that the Julphar system has the highest standards and processes to ensure consistent quality across our entire value chain – from the supply of materials through to manufacturing and approval by the leading authorities in the world.
“Our consumers deserve safe, effective and quality products, and across the Julphar system, we work hard to meet the highest standards of safety and quality. We follow stringent procedures designed to ensure the safety and quality of each of our products.
Our scientific teams are working hand in hand with MOHAP and we are following their recommendations to the letter to ensure a quick resolution.”
Home >> Healthcare & Medicine Section